Geron Corporation
NASDAQ:GERNBiotechnology
+$0.05 today
- Market cap
- $638.38M
- Beta
- 0.60
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.10
Volume 34.97M
Average 16.28M
GERN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Geron CorporationNASDAQ: GERN
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $3.64M (cash outflow) fell 81.6% year over year, behind the -51.6% change in trailing-twelve-month net income. Sequentially, it fell 87.4% from the prior quarter. Over 3 fiscal years it compounded at -15.4% a year.
Context
- Net income amounted to 46.7% of revenue in FY2025, down 180.1 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$10.44M (-87.8%) for the fiscal year ending Dec 2026, a slowdown from the -50.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.64M-87.4% QoQ
- Last fiscal yearDec 2025
- -$85.78M-50.9% YoY
- LTMMar 2026
- -$67.31M-51.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -81.6% | -63.4% | +18.2 pp |
| 1 year | -50.9% | -87.8% | -37.0 pp |
| 3-year CAGR | -15.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (85.78M) USD
- Year-over-year change
- +50.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (85.78M) | +50.9% |
| FY2024 | 2024-12-31 | (174.57M) | +5.2% |
| FY2023 | 2023-12-31 | (184.13M) | -29.8% |
| FY2022 | 2022-12-31 | (141.9M) | -22.2% |
| FY2021 | 2021-12-31 | (116.11M) | — |
Net Income vs competitors
How GERN compares with its peers on the latest reported figures
- GERN's LTM Mar 2026 net income of $67.31M is the 4th largest of the 8 companies compared; the peer median is $25.43M.
- Its year-over-year change of -51.6% is the lowest of 6, against a peer median of +127.6%.
- Net income amounts to 34.3% of revenue for GERN, versus a peer median of 32.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.61B | +85.1% | +55.7% | 27.7% | |
| LTM Mar 2026 | $364.23M | +879.7% | — | 121.5% | |
| LTM Mar 2026 | $107.79M | +391.1% | -58.2% | — | |
| LTM Mar 2026 | $67.31M | -51.6% | -15.4% | 34.3% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $63.91M | — | — | — |
| LTM Sep 2026 | $35.76M | +37.8% | -13.4% | — | |
DMRADamora Therapeutics, Inc. | LTM Jun 2024 | $25.43M | — | +50.4% | — |
| LTM Jun 2026 | $11.31M | +127.6% | +0.9% | 32.2% | |
| Peer median (excluding GERN) | $25.43M | +127.6% | +0.9% | 32.2% | |
Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (116.11M) | (141.9M) | (184.13M) | (174.57M) | (85.78M) |
| Depreciation & Amortization | 783K | 868K | 1.03M | 1.22M | 1.2M |
| Deferred Income Tax | 191K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.08M | 8M | 19.35M | 31.32M | 88K |
| Change in Working Capital | 10.52M | 5.03M | 6.06M | (68.41M) | (68.54M) |
| Accounts Receivables | (1.04M) | (1.38M) | 1.49M | (36.89M) | (377K) |
| Inventory | 1.04M | 1.38M | 0 | (37.97M) | (77.92M) |
| Accounts Payables | (232K) | 3.5M | (4.03M) | 2.44M | 2.66M |
| Other Working Capital | 10.75M | 1.52M | 8.6M | 4.02M | 7.1M |
| Other Non-Cash Items | 984K | 626K | (10.06M) | (8.18M) | 41.99M |
| Operating Cash Flow | (95.56M) | (127.38M) | (167.74M) | (218.62M) | (111.04M) |
| Capital Expenditures | (207K) | (431K) | (830K) | (680K) | (49K) |
| Acquisitions (Net) | 1.59M | (1.23M) | 179.49M | 0 | 0 |
| Purchases of Investments | (177.43M) | (258.01M) | (475.59M) | (476.93M) | (304.42M) |
| Sales of Investments | 249.59M | 320.51M | 296.1M | 371.61M | 411.72M |
| Other Investing Activities | (1.59M) | 1.23M | (179.49M) | 0 | 0 |
| Investing Cash Flow | 71.95M | 62.07M | (180.32M) | (106M) | 107.25M |
| Debt Repayment | 24.9M | 0 | 29.7M | 34.57M | 0 |
| Common Stock Issued | 20.39M | 69.92M | 213.34M | 140.73M | 2.27M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.28M | 17.35M | 118.98M | 159.08M | 0 |
| Financing Cash Flow | 48.56M | 87.26M | 362.02M | 334.37M | 2.27M |
| Effect of Forex Changes | 0 | 22K | (27K) | (12K) | 87K |
| Net Change in Cash | 24.95M | 21.97M | 13.93M | 9.74M | (1.44M) |
| Free Cash Flow | (95.76M) | (127.81M) | (168.57M) | (219.3M) | (111.09M) |
Geron Corporation
NASDAQ:GERN
Intrinsic Alpha fair value
Locked
Current Price
$0.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.